Addressing Legislation That Restricts Access to Care for Transgender Youth

Blockers are the common term for a class of medications known as gonadotropin-releasing hormone analogues (GnRHas), which suppress undesired physical changes associated with puberty.^2,6  Safety data for GnRHas are derived from their use in the treatment of central precocious puberty over the last 3 decades.⁷  In studies, researchers have described normal BMI, body composition, bone mineral density, gonadal function, and fertility in young adults who received GnRHas in childhood.⁷  Importantly, the effects of GnRHas on both luteinizing hormone pulsatility and clinical progression of puberty are reversible.²  In part because of a favorable safety profile, GnRHa use in TGD youth has increased in the United States in recent years.⁶ 

TGD youth experience psychological and physical benefits from treatment with GnRHas.^8–10  GnRHas prevent worsening distress from pubertal changes that are irreversible and incongruous with gender identity.²  GnRHas mitigate mental health comorbidities (eg, suicidality, depression, and substance use), which may stem from societal discrimination, minority stress, risk of rejection, and negative health implications associated with gender dysphoria.^8–10  GnRHas may also eliminate the need for future gender-affirming surgeries, all of which entail medical risks and can be prohibitively expensive (eg, gender-affirming mastectomy or “top” surgery, facial feminization surgery).

The small number of TGD children (∼1.9%–3.6%) who discontinue GnRHa use reflects the strength of the multidisciplinary approach to GAC, which includes a psychosocial assessment and longitudinal follow-up.¹¹  Low rates of retransition to the birth-assigned gender and high rates of progression to gender-affirming hormones likely reflect careful selection of candidates for GnRHa use by a multidisciplinary team. Consenting to GnRHa therapy does not compel TGD youth to pursue additional medical or surgical therapy but rather facilitates well-informed and carefully considered decisions about subsequent gender-affirming interventions without the stress of unwanted pubertal progression. GnRHas are thus an essential tool for promoting the overall mental health and well-being of TGD youth.^8–10 

Bell versus Tavistock also raises concerns about fertility options for TGD youth.⁴  GnRHas alone do not impact future fertility. The physical effects of these medications are considered reversible, and therefore, youth have the option of pursuing fertility preservation options before initiating gender-affirming hormones, in some cases while using GnRHa. Additionally, TGD youth have been shown to be open to a variety of family-building options and may not desire to pursue fertility preservation.¹²  The psychological toll of experiencing undesired pubertal changes must thus be weighed against the variety of perspectives on fertility among TGD youth and evolving options for fertility preservation.

Pediatric care uses widely accepted models of parent or guardian consent for interventions that are considered in the best interest of the minor, accompanied by an assent process for minors when developmentally appropriate.⁵  The practice of allowing guardians to consent for a minor’s medical care with potential lifelong benefit and/or risk is standard of care in pediatrics (eg, vaccination, oncology treatment). As the use of GnRHa has clear benefits for TGD youth, it is appropriate for guardians, without the need for court approval, to consent to this treatment on behalf of their children.^2,8–10 

Studies have revealed that by 12 years old, children have the capacity to make informed medical decisions. Under the “mature minor doctrine,” adolescents 14 to 17 years old who possess maturity and decisional capacity may provide consent for medical care. In some situations (eg, contraception or substance abuse), there is also legal precedent for obtaining consent for medical treatments directly from minors.⁵ 

Proposed legislative bans on TGD medical care in the United States selectively undermine the use of well-established consent models as they are applied to the clinical care of TGD youth.⁴  Many TGD patients possess decisional capacity, and with guardian consent and the support of a multidisciplinary team, they are able to contribute to decisions in their own best interests about GnRHas and gender-affirming hormones. Furthermore, denying TGD youth access to GnRHas to prevent irreversible secondary sex characteristics incongruent with their gender has the potential to do significant harm by worsening gender dysphoria and psychological distress.

Efforts to restrict clinicians’ ability to provide GAC must be contextualized within the long-standing history of marginalization of TGD individuals, who still face inequitable access to medical care. By undermining access to GAC, Bell versus Tavistock and proposed anti-GAC legislation in the United States threaten to deepen pre-existing inequities, leading to increased morbidity and mortality among TGD youth and disproportionately harming TGD people of color and those living in poverty.

Underrepresentation of TGD people in medical and legislative leadership roles, and as clinicians, contributes to a dearth of valuable community knowledge in these settings. In medicine, TGD people are often excluded from the creation of clinical practice guidelines directly affecting the TGD community. All efforts must be made to include TGD voices in clinical care settings by hiring TGD health care workers and developing TGD clinical advisory boards. Finally, clinicians can have a powerful voice as advocates for TGD youth by reaching out to state and federal legislators to provide them with accurate information about the importance of GAC. Inclusive practices will ensure that clinical care is affirming and will allow pediatric providers to work more effectively in opposition to the damaging restrictions imposed by laws banning GAC in the United States and worldwide.^13–29 

We thank the TGD patients and their families who allow them the privilege of participating in their care. We also thank Ariel Botta, PhD, MSW, LICSW; Jennifer Gentile, PsyD; Peter Hunt, PhD; and Francie Mandel, MSW, LICSW.

GAC

gender-affirmative medical care

GnRHa

gonadotropin-releasing hormone analogue

TGD

transgender and gender-diverse